Keppra (levetiracetam) is not a blood thinner. It is an anti-epileptic medication used to prevent and control seizures. It works in the brain by modifying how nerve cells communicate, not by affecting your blood’s ability to clot. A controlled study of healthy adults found that levetiracetam had no significant effect on platelet function, clotting factors, or blood cell counts compared to placebo.
How Keppra Actually Works
Keppra belongs to a class of drugs called anticonvulsants. Unlike blood thinners, which target clotting proteins or platelets in your bloodstream, Keppra acts entirely in the nervous system. It binds to a specific protein on the surface of nerve cells that helps regulate the release of chemical signals. By doing so, it reduces the abnormal electrical activity that causes seizures. Its chemical structure is unrelated to other seizure medications and has no known mechanism for thinning the blood.
What the Research Shows About Blood Clotting
A double-blind, placebo-controlled crossover study published in the Journal of Clinical Medicine tested whether a single 1,000 mg dose of levetiracetam affected platelet function in 12 healthy adults. The researchers measured three key markers of clotting ability: thrombin binding (how well platelets respond to a clotting signal), fibrinogen binding (how well platelets stick together), and a marker called P-selectin that indicates platelet activation. Levetiracetam showed no significant effect on any of these tests, and all blood cell counts remained unchanged.
The researchers noted that while scattered case reports had raised the possibility that Keppra might affect platelets, no controlled studies supported that concern. Their findings aligned with the broader body of evidence: Keppra does not act as a blood thinner in any meaningful way.
Minor Blood Count Changes Are Possible
Although Keppra does not thin the blood, it can cause small, mostly insignificant changes in blood counts. In clinical trials, patients taking Keppra showed minor decreases in red blood cell counts, hemoglobin, and a type of white blood cell called neutrophils compared to placebo. These differences were statistically detectable but clinically tiny. For example, average hemoglobin dropped by just 0.09 g/dL, a change too small to cause symptoms or require treatment in most people.
In rare postmarketing reports, more serious blood abnormalities have occurred, including very low platelet counts (thrombocytopenia) and severely reduced white blood cells. These are uncommon. In one FDA clinical review, only 2 patients out of the study population developed thrombocytopenia during treatment, and in both cases the events were judged mild to moderate and unrelated to the drug. Neither patient required any change in treatment, and their platelet counts recovered on their own.
If you notice unusual bruising, frequent infections, or unexplained fatigue while taking Keppra, a simple blood test can check whether your counts have shifted.
Keppra and Blood Thinner Interactions
One reason people may wonder about Keppra and blood thinning is that several common anticoagulants appear on its drug interaction list. The Mayo Clinic notes that combining Keppra with apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), or edoxaban (Savella) is “usually not recommended” without a dose adjustment. This does not mean Keppra acts like these drugs. Instead, it means the medications can affect each other’s levels in the body, potentially making the blood thinner more or less effective than expected.
If you take both Keppra and a blood thinner, your prescriber may monitor your blood work more closely or adjust dosing. The interaction is about how the drugs are processed, not about Keppra itself having anticoagulant properties.
Keppra Is Not Stopped Before Surgery
One practical way to understand that Keppra is not a blood thinner: it is never stopped before surgery the way actual blood thinners are. Medications like warfarin, Eliquis, and Xarelto are routinely paused days before a procedure to reduce bleeding risk. Keppra is the opposite. Perioperative guidelines from the UK Clinical Pharmacy Association explicitly state that Keppra should be continued through both elective and emergency surgery. Stopping it abruptly risks triggering rebound seizures or even status epilepticus, a prolonged seizure emergency. If you cannot take pills after surgery, the same dose can be given intravenously.
This is a clear signal that surgical teams do not consider Keppra a bleeding risk. Its role before, during, and after a procedure is to keep seizures under control, nothing more.